[go: up one dir, main page]

MX2007012991A - Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas. - Google Patents

Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.

Info

Publication number
MX2007012991A
MX2007012991A MX2007012991A MX2007012991A MX2007012991A MX 2007012991 A MX2007012991 A MX 2007012991A MX 2007012991 A MX2007012991 A MX 2007012991A MX 2007012991 A MX2007012991 A MX 2007012991A MX 2007012991 A MX2007012991 A MX 2007012991A
Authority
MX
Mexico
Prior art keywords
crystalline solid
halofenate
amorphous forms
hyperlipidemia
diabetes
Prior art date
Application number
MX2007012991A
Other languages
English (en)
Inventor
Jason A Hanko
Edward D Daugs
Eric J Hagen
David H Louks
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of MX2007012991A publication Critical patent/MX2007012991A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona formas solidas cristalinas y amorfas de halofenato (-). Las formas solidas cristalinas pueden utilizarse en diversas composiciones farmaceuticas y son particularmente efectivas para la prevencion y/o tratamiento de condiciones asociadas con la deposicion de lipidos en sangre en un mamifero, particularmente aquellas enfermedades relacionadas con diabetes Tipo 2 e hiperlipidemia. La invencion se refiere tambien a un metodo para prevenir o tratar diabetes Tipo 2 e hiperlipidemia en un mamifero, que comprende la etapa de administrar una cantidad terapeuticamente efectiva de formas solidas cristalinas y amorfas de halofenato (-).
MX2007012991A 2005-04-20 2006-04-20 Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas. MX2007012991A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67365505P 2005-04-20 2005-04-20
PCT/US2006/015163 WO2006113917A1 (en) 2005-04-20 2006-04-20 Crystalline solid and amorphous forms of (-)- halofenate

Publications (1)

Publication Number Publication Date
MX2007012991A true MX2007012991A (es) 2008-03-13

Family

ID=37115499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012991A MX2007012991A (es) 2005-04-20 2006-04-20 Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.

Country Status (15)

Country Link
US (5) US8203019B2 (es)
EP (1) EP1877362A1 (es)
JP (1) JP2008538570A (es)
KR (1) KR101372271B1 (es)
CN (1) CN101163660A (es)
BR (1) BRPI0610782A2 (es)
CA (1) CA2606279C (es)
CR (1) CR9516A (es)
EA (1) EA200702274A1 (es)
IL (1) IL186664A (es)
MX (1) MX2007012991A (es)
NO (1) NO20075831L (es)
UA (1) UA96571C2 (es)
WO (1) WO2006113917A1 (es)
ZA (1) ZA200709015B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200702274A1 (ru) * 2005-04-20 2008-04-28 Метаболекс, Инк. Твёрдые кристаллические и аморфные формы (-)-галофената и способ их получения, фармацевтическая композиция на их основе и способ лечения
WO2009121940A1 (en) * 2008-04-03 2009-10-08 Janssen Pharmaceutica Nv Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester
CN116033891A (zh) * 2020-09-03 2023-04-28 菲利普莫里斯生产公司 冷冻干燥的低吸湿性活性粉末组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953490A (en) 1972-07-13 1976-04-27 Merck & Co., Inc. Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
EA200702274A1 (ru) * 2005-04-20 2008-04-28 Метаболекс, Инк. Твёрдые кристаллические и аморфные формы (-)-галофената и способ их получения, фармацевтическая композиция на их основе и способ лечения

Also Published As

Publication number Publication date
NO20075831L (no) 2008-01-18
IL186664A0 (en) 2008-01-20
US20120232303A1 (en) 2012-09-13
US8203019B2 (en) 2012-06-19
KR101372271B1 (ko) 2014-03-17
US9233914B2 (en) 2016-01-12
CN101163660A (zh) 2008-04-16
CR9516A (es) 2008-03-06
US20160280636A1 (en) 2016-09-29
UA96571C2 (uk) 2011-11-25
IL186664A (en) 2013-10-31
US8507719B2 (en) 2013-08-13
ZA200709015B (en) 2008-12-31
US20140024852A1 (en) 2014-01-23
WO2006113917A1 (en) 2006-10-26
US9845285B2 (en) 2017-12-19
JP2008538570A (ja) 2008-10-30
US20080221018A1 (en) 2008-09-11
EP1877362A1 (en) 2008-01-16
BRPI0610782A2 (pt) 2017-01-31
US8993797B2 (en) 2015-03-31
EA200702274A1 (ru) 2008-04-28
CA2606279C (en) 2015-01-06
AU2006236153A2 (en) 2006-10-26
AU2006236153A1 (en) 2006-10-26
KR20070122567A (ko) 2007-12-31
WO2006113917A9 (en) 2008-02-14
CA2606279A1 (en) 2006-10-26
US20150225333A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2009044392A3 (en) Novel sirna structures
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2007112000A3 (en) Treatment of pain
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2008033464A3 (en) Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
IL193252A0 (en) N-hydroxyacrylamide compounds
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
TW200639159A (en) Treatment of pain
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
CA2632207C (en) Use of calcitonin for the treatment of ra
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2008036733A3 (en) Methods for treatment of vesicle transport disorders
WO2006121995A3 (en) Methods for treating nephrolithiasis
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: THERAVANCE RESPIRATORY COMPANY, LLC

FG Grant or registration